Search

Your search keyword '"Maziarz, Richard T."' showing total 1,626 results

Search Constraints

Start Over You searched for: Author "Maziarz, Richard T." Remove constraint Author: "Maziarz, Richard T."
1,626 results on '"Maziarz, Richard T."'

Search Results

1. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

2. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

3. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

5. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome

8. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year

9. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

11. Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques

13. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

22. Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.

25. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

26. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups

27. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

29. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

33. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma

35. Access to Allogeneic Hematopoietic Cell Transplant for Patients with Hematologic Malignancies in Oregon

36. JAK1 Inhibition during CAR-T Cell Treatment Results in Reduction in Various Cytokines That Correlate with Cytokine Release Syndrome (CRS) and Immune Effector Cell (IEC)–Associated Neurotoxicity Syndrome (ICANS) Grades

37. Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open-Label Expanded Access Program (EAP)

38. Impact of ABO Compatibility on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT): Ptcy Impacts Platelet Engraftment, Independent of ABO Compatibility

39. Long-Term Durable Responses in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL) Treated with Tisagenlecleucel and Its Association with Persistence of Chimeric Antigen Receptor (CAR) T Cells

40. Discovery of an Inherited Variant Associated with Susceptibility to Secondary Acute Lymphoblastic Leukemia (ALL) after Lenalidomide Maintenance and Autologous HCT for Multiple Myeloma (MM)

41. The Impact of Telehealth Visits on Access to Transplant Care for Recipients of Allogeneic Hematopoietic Cell Transplantation in the State of Oregon

42. Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel: A Cell Therapy Consortium Study

43. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102

44. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

45. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome

48. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma

49. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS

Catalog

Books, media, physical & digital resources